GlassScriptPhysician profile
Amar N Goyal
NPI 1700971819
$7,056.69
in general payments reported to CMS, 2019-2025
42 companies · $1,402 in 2025
The $1,402 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $839 · 2020: $1,047 · 2021: $905 · 2022: $1,393 · 2023: $756 · 2024: $715 · 2025: $1,402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,297 · Travel and Lodging: $576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,297.37 |
| Travel and Lodging | $575.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $976.04 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $924.88 | 2019-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $787.61 | 2019-2025 | Xtampza, Belbuca |
| Si-Bone, INC. | $608.86 | 2025 | |
| Abbvie INC. | $537.08 | 2021-2025 | |
| Pfizer INC. | $382.63 | 2019-2025 | |
| Protega Pharmaceutials INC | $318.64 | 2022-2025 | Roxybond |
| Medtronic, INC. | $317.87 | 2021-2023 | Intellis Adaptivestim |
| Scilex Pharmaceuticals INC. | $285.52 | 2019-2025 | |
| Lilly USA, LLC | $177.52 | 2020-2023 | Emgality, Reyvow |
| Biohaven Pharmaceutical Holding Company LTD. | $170.83 | 2022 | |
| Boston Scientific Corporation | $159.49 | 2019-2024 | |
| Arbor Pharmaceuticals, INC. | $142.24 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $113.56 | 2021 | |
| Amgen INC. | $107.79 | 2019-2024 | Prolia |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amar Goyal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.